Navigation Links
Hard to Treat Diseases (HTDS.PK) Business Summary Update
Date:12/7/2009

ds or phrases "can be", "expects", "may affect", "believed", "estimate", "project" and similar words and phrases are intended to identify such forward-looking statements. Hard to Treat Diseases Inc. cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases Inc. is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases Inc.'s control. In addition to those discussed in Hard to Treat Diseases Inc.'s press releases, public filings, and statements by Hard to Treat Diseases Inc.'s management, including, but not limited to, Hard to Treat Diseases Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases Inc.'s ability to raise additional capital to fund future operations, Hard to Treat Diseases Inc.'s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities, and in identifying contracts which match Hard to Treat Diseases Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: For any investor relations matters, please contact www.minamargroup.net/helpdesk; Investor Relations Department Inquiry, www.minamargroup.net (IR); For (M&A) and
'/>"/>

SOURCE Hard to Treat Diseases
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Nutra Pharma Completes FDA Submission for Nyloxin OTC and Nyloxin Rx -- Over-the-Counter and Prescription Treatments for Chronic Pain
2. New study finds barriers to pain treatment in children with sickle cell disease
3. Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease
4. New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer
5. New Gene Findings Will Help Guide Treatment in Infant Leukemia
6. Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders
7. Epilepsy Patients Caught in Treatment Gap and Not Getting State-of-the-Art Care
8. Epilepsy patients caught in treatment gap are not getting state-of-the-art care
9. Lexi-Comp Focused on Improving Patient Communication in Healthcare Institutions Treating Diverse Patient Populations
10. Miami Dentist Dr. H.A. Nassery Treats Local Teen Golf Star and Helps Improve Her Performance
11. NYU Langone Medical Center Study Shows VNS Therapy is a Safe and Effective Treatment for Refractory Epilepsy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... 2015 Ultraman Florida is a grueling ... 261.4 mile bike, and 52.4 mile run. Christian Isakson ... 24:45:45. , "This race was awesome and tough," Isakson ... and sponsors for supporting me through every part of ... a total of 40 select participants invited from across ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 FDA’s New ... , **FDAnews Webinar**, March 24, 2015 — 1:30 p.m. ... investigators generally know within four hours of an inspection ... manufacturer is on their “good” list, they’ll merely ask ... a manufacturer is on the “bad” list, the manufacturer ...
(Date:3/4/2015)... Concord, NH (PRWEB) March 04, 2015 ... the natural frozen food category, will attend this year’s ... from its newest product line. With this new line, ... meals in the natural channel, continues its commitment to ... the fastest growing frozen brand in the natural channel, ...
(Date:3/4/2015)... 2015 The print component of “Organic ... Francisco Chronicle with a circulation of approximately 173,000 copies ... component is distributed nationally through a vast social media ... and partner outlets. To explore the digital version of ... is composed of heat-dried microbes that have digested the ...
(Date:3/4/2015)... 04, 2015 The New Mel Brooks ... music, will be performed by the award-winning Drama Department ... this March 6-22, 2015, on Fridays, Saturdays and Sundays. ... High School (27118 Silver Spur Road, Rolling Hills ... the program or may be purchased on-line at ...
Breaking Medicine News(10 mins):Health News:Living Fuel Champion Christian Isakson Finishes Second In UltraMan Florida Test of Endurance 2Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 2Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 3Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 4Health News:Fastest Growing Frozen Brand in Natural Channel Showcases New Line at Expo West 2015 2Health News:Fastest Growing Frozen Brand in Natural Channel Showcases New Line at Expo West 2015 3Health News:The New Mel Brooks Musical Young Frankenstein Performance March 6-March 22, 2015, by the Award Winning Drama Department at Peninsula High School, Rolling Hills 2
... Children With Food,Allergies, FAIRFAX, Va., Feb. 11 ... announce the release of two animated,DVDs that both entertain ... Couldn,t Eat Peanuts ... Goes to School and,Alexander, the ... help,children cope with their own allergies and teach other ...
... Corporation,(NYSE: CSK ), a leading international manufacturer ... of printed pharmaceutical,leaflets in North America, today announced ... Long Island, N.Y., and relocating,from its current location ... business has grown substantially since we moved to ...
... from seven countries, including teams of robotics and brain ... been set up with the aim of imitating nature. ... in the animal kingdom, the multinational team is developing ... whiskered robot will be able to quickly locate, identify ...
... the American Academy ... of Dermatology, ... indicates the 8-oxo-guanine DNA glycosylase (OGG1),encapsulated in liposomes is an effective ... and increasing,collagen production in UV irradiated skin cells. The data was ...
... 11 /PRNewswire-FirstCall/ - Neurochem Inc. (NASDAQ:,NRMX; TSX: NRM) ... Dr.,Francesco Bellini, Neurochem,s Chairman, President and Chief Executive,Officer, ... the new,nutraceutical business, will present Neurochem,s strategy at ... held at the Waldorf-Astoria, in New York,(NY). The ...
... Complex fibroadenomas have a low incidence of malignancy, so ... and avoid surgical biopsy, according to a new study ... Medical Center in Jerusalem. , A fibroadenoma is a ... young women. They are not usually associated with breast ...
Cached Medicine News:Health News:New Alexander, the Elephant Who Couldn't Eat Peanuts DVDs Help Children With Food Allergies 2Health News:New Alexander, the Elephant Who Couldn't Eat Peanuts DVDs Help Children With Food Allergies 3Health News:Chesapeake to Expand and Relocate North American Pharmaceutical Packaging Operation 2Health News:Scientists from Europe, Israel and the US develop robotic rats to aid in rescue missions 2Health News:Scientists from Europe, Israel and the US develop robotic rats to aid in rescue missions 3Health News:AGI Dermatics Data Indicates 8 Oxo-Guanine Repair Enzyme OGG1 Encapsulated in Liposomes, Reduces MMP-1, Increases Collagen and Enhances DNA Repair 2Health News:AGI Dermatics Data Indicates 8 Oxo-Guanine Repair Enzyme OGG1 Encapsulated in Liposomes, Reduces MMP-1, Increases Collagen and Enhances DNA Repair 3Health News:Neurochem to present at 2008 BIO CEO & Investor Conference - Presentation will be Web cast live 2Health News:Study finds patients with complex fibroadenomas can avoid surgery 2
(Date:3/4/2015)... , March 4, 2015 Asterias Biotherapeutics, ... the emerging field of regenerative medicine, today announced that ... will ring The Opening Bell ® of the ... 2015. Asterias began trading as an NYSE MKT listed ... York Stock Exchange is a trusted partner to Asterias ...
(Date:3/4/2015)... OAKS, Calif. , March 4, 2015 ... Board of Directors today declared a $0.79 per share ... will be paid on June 5, 2015, to all ... on May 14, 2015.  About Amgen ... for patients suffering from serious illnesses by discovering, developing, ...
(Date:3/4/2015)... 4, 2015  NxStage Medical, Inc. (Nasdaq: NXTM ... that Jeffrey H. Burbank , Chief Executive Officer, will ... Miami, FL on Wednesday, March 11 th ... the event will be made available at http://ir.nxstage.com ... NxStage NxStage Medical, Inc. (Nasdaq: NXTM ...
Breaking Medicine Technology:Asterias Biotherapeutics to Ring Opening Bell at New York Stock Exchange 2Asterias Biotherapeutics to Ring Opening Bell at New York Stock Exchange 3Amgen Announces 2015 Second Quarter Dividend 2Amgen Announces 2015 Second Quarter Dividend 3NxStage to Present at the Barclays Capital Global Healthcare Conference 2
... Based on its recent analysis of the personal emergency ... with the 2010 North American Frost & Sullivan Award ... BeClose System and its applications in the "aging independently" ... While PERS have provided a health monitoring service for ...
... Inc. (Nasdaq: OPTR ) today announced that the ... the Company,s New Drug Application (NDA) for fidaxomicin for the ... reducing the risk of recurrence when used for treatment of ... for six-month Priority Review, and has assigned a Prescription Drug ...
Cached Medicine Technology:Frost & Sullivan Recognizes BeClose as a Technology Innovator for 'Aging Independently' in North America 2Frost & Sullivan Recognizes BeClose as a Technology Innovator for 'Aging Independently' in North America 3Frost & Sullivan Recognizes BeClose as a Technology Innovator for 'Aging Independently' in North America 4Optimer Pharmaceuticals Announces FDA Acceptance of NDA for Filing and Designation of Priority Review for Fidaxomicin for the Treatment of Clostridium difficile Infection (CDI) 2Optimer Pharmaceuticals Announces FDA Acceptance of NDA for Filing and Designation of Priority Review for Fidaxomicin for the Treatment of Clostridium difficile Infection (CDI) 3Optimer Pharmaceuticals Announces FDA Acceptance of NDA for Filing and Designation of Priority Review for Fidaxomicin for the Treatment of Clostridium difficile Infection (CDI) 4
Shandon Slide Mailers and Envelopes...
Shandon Stackable Slide Storage Cabinet...
Shandon Slide File Storage System...
Shandon Plastic Slide Boxes...
Medicine Products: